Cross sectional study of the clinical characteristics of French primary care patients with COVID-19.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
14 06 2021
Historique:
received: 10 10 2020
accepted: 25 05 2021
entrez: 15 6 2021
pubmed: 16 6 2021
medline: 25 6 2021
Statut: epublish

Résumé

The early identification of patients suffering from SARS-CoV-2 infection in primary care is of outmost importance in the current pandemic. The objective of this study was to describe the clinical characteristics of primary care patients who tested positive for SARS-CoV-2. We conducted a cross-sectional study between March 24 and May 7, 2020, involving consecutive patients undergoing RT-PCR testing in two community-based laboratories in Lyon (France) for a suspicion of COVID-19. We examined the association between symptoms and a positive test using univariable and multivariable logistic regression, adjusted for clustering within laboratories, and calculated the diagnostic performance of these symptoms. Of the 1561 patients tested, 1543 patients (99%) agreed to participate. Among them, 253 were positive for SARS-CoV-2 (16%). The three most frequently reported 'ear-nose-throat' and non-'ear-nose-throat' symptoms in patients who tested positive were dry throat (42%), loss of smell (36%) and loss of taste (31%), respectively fever (58%), cough (52%) and headache (45%). In multivariable analyses, loss of taste (OR 3.8 [95% CI 3.3-4.4], p-value < 0.001), loss of smell (OR 3.0 [95% CI 1.9-4.8], p < 0.001), muscle pain (OR 1.6 [95% CI 1.2-2.0], p = 0.001) and dry nose (OR 1.3 [95% CI 1.1-1.6], p = 0.01) were significantly associated with a positive result. In contrast, sore throat (OR 0.6 [95% CI 0.4-0.8], p = 0.003), stuffy nose (OR 0.6 [95% CI 0.6-0.7], p < 0.001), diarrhea (OR 0.6 [95% CI 0.5-0.6], p < 0.001) and dyspnea (OR 0.5 [95% CI 0.3-0.7], p < 0.001) were inversely associated with a positive test. The combination of loss of taste or smell had the highest diagnostic performance (OR 6.7 [95% CI 5.9-7.5], sensitivity 44.7% [95% CI 38.4-51.0], specificity 90.8% [95% CI 89.1-92.3]). No other combination of symptoms had a higher performance. Our data could contribute to the triage and early identification of new clusters of cases.

Identifiants

pubmed: 34127693
doi: 10.1038/s41598-021-91685-3
pii: 10.1038/s41598-021-91685-3
pmc: PMC8203628
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12492

Références

Clin Infect Dis. 2020 Jul 28;71(15):889-890
pubmed: 32215618
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
J Med Virol. 2020 Jun;92(6):612-617
pubmed: 32108351
Eur J Intern Med. 2021 Apr;86:41-47
pubmed: 33579579
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Intern Med. 2020 Sep;288(3):335-344
pubmed: 32352202
PLoS One. 2020 Aug 21;15(8):e0237960
pubmed: 32822413
PLoS One. 2021 Feb 24;16(2):e0246513
pubmed: 33626045
Euro Surveill. 2020 Feb;25(6):
pubmed: 32070465
J Neurochem. 2021 May;157(4):930-943
pubmed: 32970861
J Gen Intern Med. 2020 May;35(5):1545-1549
pubmed: 32133578
Sci Rep. 2020 Nov 13;10(1):19765
pubmed: 33188232
JAMA Netw Open. 2020 Jun 1;3(6):e2012270
pubmed: 32543702
JMIR Public Health Surveill. 2020 Sep 18;6(3):e21866
pubmed: 32650305
J Infect. 2020 Dec;81(6):937-943
pubmed: 32998038
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
Fam Pract. 2020 Nov 28;37(6):866-867
pubmed: 32719842
CMAJ. 2020 Jun 29;192(26):E702-E707
pubmed: 32461325
J Clin Med. 2021 Feb 03;10(4):
pubmed: 33546319
JAMA. 2020 Feb 25;323(8):707-708
pubmed: 31971553
Euro Surveill. 2020 Mar;25(9):
pubmed: 32156329
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Gen Intern Med. 2020 Aug;35(8):2502-2504
pubmed: 32519322
Int J Dermatol. 2020 Jun;59(6):739-743
pubmed: 32329897

Auteurs

Paul Sebo (P)

Primary Care Unit, Faculty of Medicine, University of Geneva, Geneva, Switzerland. paulsebo@hotmail.com.

Benoit Tudrej (B)

University College of General Medicine, University Claude Bernard Lyon 1, Lyon, France.
Mermoz Primary Health Centre, Lyon, France.

Julie Lourdaux (J)

Cerballiance Rhône-Alpes Laboratory, Lyon, France.

Clara Cuzin (C)

University College of General Medicine, University Claude Bernard Lyon 1, Lyon, France.

Martin Floquet (M)

University College of General Medicine, University Claude Bernard Lyon 1, Lyon, France.

Dagmar M Haller (DM)

Primary Care Unit, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Hubert Maisonneuve (H)

Primary Care Unit, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
University College of General Medicine, University Claude Bernard Lyon 1, Lyon, France.
Mermoz Primary Health Centre, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH